Ironwood Pharmaceuticals, which discovers, develops and intends to commercialize innovative medicines targeting therapeutic needs, filed on Friday with the SEC to raise up to $173 million in an initial public offering. The Boston-based company, which was founded in 1998 and booked $32 million in sales over the last 12 months, plans to list on the NASDAQ under the symbol IRWD. J.P. Morgan, Morgan Stanley and Credit Suisse are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.
